Overcoming mutation-based resistance to antiandrogens with rational drug design

The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer. Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Balbas, Minna D, Evans, Michael J, Hosfield, David J, Wongvipat, John, Arora, Vivek K, Watson, Philip A, Chen, Yu, Greene, Geoffrey L, Shen, Yang, Sawyers, Charles L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2013
Materias:
Human Biology and Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622181/
https://www.ncbi.nlm.nih.gov/pubmed/23580326
http://dx.doi.org/10.7554/eLife.00499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622181/
https://www.ncbi.nlm.nih.gov/pubmed/23580326
http://dx.doi.org/10.7554/eLife.00499

Ejemplares similares